A Phase 1 interventional study of ALG-055009 and Placebo in NASH - Nonalcoholic Steatohepatitis, sponsored by Aligos Therapeutics. Completed at 1 site in France. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-09-25.
Sponsored by Aligos Therapeutics · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 104 studies in Non-alcoholic Fatty Liver Disease with a site in France — 20 open to participants now, 26 under way, 8 of them phase 3. Non-alcoholic Fatty Liver Disease · France.
Among the 104 studies in Non-alcoholic Fatty Liver Disease with a site in France, this one is the 66th largest by enrollment of the 84 interventional ones that give a count, is one of 16 that started in 2021, is the only one in phase 1, and was the 80th registered.
1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 323 are open to participants now.
Browse Non-alcoholic Fatty Liver Disease studies →20 of the 104 studies in Non-alcoholic Fatty Liver Disease with a site in France are open now. Recruiting first, the newest first:
GlaxoSmithKline · Sites in France, United States, Australia and 5 more countries
Ages 18–75
Eli Lilly and Company · Sites in France, United States, Argentina and 31 more countries
Ages 18+
University Hospital, Angers · Sites in France
Ages 18+
E-Scopics · Sites in France
Ages 18–80
Akero Therapeutics, Inc · Sites in France, United States, Argentina and 20 more countries
Ages 18–80
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 220 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 125 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
104 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 40 · Phase 3 18 · Phase 4 1
First in 1997; this study’s year is marked. 16 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 98 is above the median of 60 across 1,177 interventional studies indexed under Non-alcoholic Fatty Liver Disease.
Median enrollment 192 across the 84 interventional studies, 228 across the 20 observational. Of the 64 that completed or were terminated, 37 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
62 of 104 have an industry lead sponsor. The 10 most frequent:
Aligos Therapeutics is the lead sponsor of 15 studies on the registry; none are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 2 (29%) have results posted.
Aligos Therapeutics has 2 studies filed under Non-alcoholic Fatty Liver Disease — fewer than ten, so there is no comparison to draw.
2 of the studies in Non-alcoholic Fatty Liver Disease with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06626074University Hospital, AngersExploratory Study of MRI Biomarkers of NASH | 2027-09-05 |
| NCT05881005University Hospital, AngersNAC- NAFLD And Cushing | 2027-09-28 |
Add all 2 to your calendar (.ics) → With an account.
Among the 104 studies in Non-alcoholic Fatty Liver Disease with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A Randomized Study of ALG-055009 Drug to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses in Healthy Volunteers and Subjects with Hyperlipidemia
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Inclusion Criteria for Subjects with Mild Hyperlipidemia:
Exclusion Criteria for All Subjects:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Oral dose(s) of ALG-055009 in Healthy Volunteer or subjects with mild hyperlipidemia once daily up to 14 days
Drug: ALG-055009
Oral dose(s) of placebo in Healthy Volunteer or subjects with mild hyperlipidemia once daily up to 14 days
Drug: Placebo
Single or multiple doses of ALG-055009
Single or multiple doses of Placebo
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
The number and severity of treatment emergent adverse events as assessed by DAIDS v2.1
Time frame: Up to 14 days for Part 1
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
The number and severity of treatment emergent adverse events as assessed by DAIDS v2.1
Time frame: Up to 28 days for Part 2
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
The number and severity of treatment emergent adverse events as assessed by DAIDS v2.1
Time frame: Up to 35 days for Part 3
Maximum Plasma Concentration [Cmax]
Pharmacokinetic parameters of ALG-055009 in plasma
Time frame: Predose (between -0.25 hours and 0 hours) up to 35 Days
Area under the concentration time curve [AUC]
Pharmacokinetic parameters of ALG-055009 in plasma
Time frame: Predose (between -0.25 hours and 0 hours) up to 35 Days
Time to maximum plasma concentration [Tmax]
Pharmacokinetic parameters of ALG-055009 in plasma
Time frame: Predose (between -0.25 hours and 0 hours) up to 35 Days
Half-life [t1/2]
Pharmacokinetic parameters of ALG-055009 in plasma
Time frame: Predose (between -0.25 hours and 0 hours) up to 35 Days
Minimum Plasma Concentration [Cmin]
Pharmacokinetic parameters of ALG-055009 in plasma
Time frame: Predose (between -0.25 hours and 0 hours) up to 35 Days
Change in lipid / lipoprotein levels from baseline through Day 28 in Multiple Dose in Subjects with Mild Hyperlipidemia
Time frame: Screening, Day -1 to Day 28
Ran from Dec 2021 to primary completion in Jun 2023, 18 months.
Of 104 industry-sponsored phase 1 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 18 months is above that.
Counting every sponsor, half of 125 studies reached it within 10 months; a quarter within 5 and three quarters within 21.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: ALG-055009
Non-alcoholic Fatty Liver Disease →
Aligos Therapeutics